Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/14/2025

Contrave Dosing and Management Guidelines

Dosing Schedule

  • The American Gastroenterological Association recommends an initial dose of one tablet (naltrexone 8 mg/bupropion 90 mg) once daily in the morning for Week 1, with gradual weekly increases to the target dose, for a patient taking medications such as Imovane and lorazepam 1, 3
  • The dosing schedule for Contrave involves increasing to one tablet twice daily (morning and evening) by Week 2, and further adjustments based on patient response, with the target dose being two tablets twice daily (total daily dose: naltrexone 32 mg/bupropion 360 mg) 1, 2, 4

Important Considerations with Concurrent Medications

  • When using Contrave with benzodiazepines like lorazepam, careful monitoring is necessary due to the potential interaction with bupropion, which lowers the seizure threshold 2, 5
  • The use of zopiclone (Imovane) with Contrave requires monitoring for potential additive CNS effects, although there are no specific contraindications 2

Efficacy and Monitoring Parameters

  • Assessing efficacy at 12 weeks is recommended, with discontinuation if a 5% weight loss is not achieved, based on guidelines from the American Diabetes Association 1, 3
  • Expected weight loss with Contrave is in the range of 2.0-4.1 kg, with 36-57% of patients achieving ≥5% weight loss, according to data from the American Diabetes Association 4, 6

Contraindications and Precautions

  • Uncontrolled hypertension is a contraindication for Contrave, as stated by the American Heart Association, due to the potential for increased blood pressure and heart rate 2, 7
  • A history of seizures or conditions predisposing to seizures is a contraindication due to the risk associated with bupropion, as advised by the American Academy of Neurology 1, 2
  • Pregnancy or planning pregnancy is a precaution, with recommendations from the American College of Obstetricians and Gynecologists to avoid use due to potential risks 4, 8